ProLung Names Director of Marketing and Business Development

ProLung, Inc., the leader in innovative predictive analytics technology and non-invasive tests for the risk stratification of lung cancer, announced today the promotion of Ryan Snow as the Director of Marketing and Business Development. Mr. Snow has been with the Company for three years and performed in multiple capacities, previously serving as the European Development Director.

ProLung, Inc. Announces Closing of Private Placement Transaction with Proceeds of $8.2 million

ProLung, Inc., the leader in innovative predictive analytics technology and non-invasive tests for the risk stratification of lung cancer, announced today the successful closing of its private placement. The private offering was expected to raise $5.2 million and was oversubscribed by $3.0 million to a total of $8.2 million.

ProLung Selected to Participate at Upcoming Cavendish Global Health Impact Forum

ProLung, Inc., a leader in innovative predictive analytics technology and non-invasive biomarkers for the risk stratification of lung cancer, announced today it has been selected to present at the upcoming Cavendish Global Health Impact Forum taking place May 7-9, 2017 in Washington, DC, co-hosted with the Virginia Biotechnology Association (VirginiaBio).

ProLung Announces the Appointment of Dr. Robin L. Smith to its Board of Directors

ProLung, a predictive analytics and risk stratification company that has developed a novel, cost effective, and non-invasive test to identify cancerous and noncancerous lung nodules, announced today that Robin L. Smith, MD, MBA, has joined the Company’s Board of Directors.

ProLungdx EPN Scan® Confirms Performance in Early Lung Cancer Risk Assessment

Fresh Medical Laboratories, Inc., doing business as ProLungdx™, today announced the initial results of its ongoing European Lung Cancer Registry.  When the Electro Pulmonary Nodule (EPN) Scan was administered to patients with lung nodules suspicious for cancer, the scan demonstrated results consistent with earlier research performed at Johns Hopkins and published in the Journal of Thoracic Oncology.